Defining Substance Use Disorders: The Need for Peripheral Biomarkers

被引:15
作者
Bough, Kristopher J. [1 ]
Pollock, Jonathan D. [1 ]
机构
[1] NIDA, NIH, Rockville, MD 20852 USA
关键词
ALCOHOL DEPENDENCE; DNA METHYLATION; SYSTEMS PHARMACOLOGY; CANNABIS SMOKERS; WHOLE-BLOOD; ADDICTION; OPRM1; BRAIN; DELTA(9)-TETRAHYDROCANNABINOL; ASSOCIATION;
D O I
10.1016/j.molmed.2017.12.009
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Addiction is a brain disease, and current diagnostic criteria for substance use disorders (SUDs) are qualitative. Nevertheless, scientific advances are beginning to characterize neurobiological domains. Combining multiple units of measure may provide an opportunity to deconstruct the heterogeneities of a SUD and define endophenotypes by using peripheral biospecimens. There are several recent examples of potential biomarker types that can be examined, together with their categorical applications for SUDs. We propose that, in conjunction with rapidly advancing statistical and mathematical modeling techniques, there is now a unique opportunity for the discovery of composite biomarkers within specific domains of addiction; these may lay the foundation for future biomarker qualification, with important implications for drug development and medical care.
引用
收藏
页码:109 / 120
页数:12
相关论文
共 57 条
  • [21] Peripheral Biomarkers Revisited: Integrative Profiling of Peripheral Samples for Psychiatric Research
    Hayashi-Takagi, Akiko
    Vawter, Marquis P.
    Iwamoto, Kazuya
    [J]. BIOLOGICAL PSYCHIATRY, 2014, 75 (12) : 920 - 928
  • [22] Low μ-Opioid Receptor Status in Alcohol Dependence Identified by Combined Positron Emission Tomography and Post-Mortem Brain Analysis
    Hermann, Derik
    Hirth, Natalie
    Reimold, Matthias
    Batra, Anil
    Smolka, Michael N.
    Hoffmann, Sabine
    Kiefer, Falk
    Noori, Hamid R.
    Sommer, Wolfgang H.
    Reischl, Gerald
    la Fougere, Christian
    Mann, Karl
    Spanagel, Rainer
    Hansson, Anita C.
    [J]. NEUROPSYCHOPHARMACOLOGY, 2017, 42 (03) : 606 - 614
  • [23] Heymann X., 2018, TRENDS MOL MED
  • [24] Huestis X., 2018, TRENDS MOL MED
  • [25] Predictive model accuracy in estimating last Δ9-tetrahydrocannabinol (THC) intake from plasma and whole blood cannabinoid concentrations in chronic, daily cannabis smokers administered subchronic oral THC
    Karschner, Erin L.
    Schwope, David M.
    Schwilke, Eugene W.
    Goodwin, Robert S.
    Kelly, Deanna L.
    Gorelick, David A.
    Huestis, Marilyn A.
    [J]. DRUG AND ALCOHOL DEPENDENCE, 2012, 125 (03) : 313 - 319
  • [26] Do Δ9-tetrahydrocannabinol concentrations indicate recent use in chronic cannabis users?
    Karschner, Erin L.
    Schwilke, Eugene W.
    Lowe, Ross H.
    Darwin, W. David
    Pope, Harrison G.
    Herning, Ronald
    Cadet, Jean L.
    Huestis, Marilyn A.
    [J]. ADDICTION, 2009, 104 (12) : 2041 - 2048
  • [27] Implications of Plasma Δ9-Tetrahydrocannabinol, 11-Hydroxy-THC, and 11-nor-9-Carboxy-THC Concentrations in Chronic Cannabis Smokers
    Karschner, Erin L.
    Schwilke, Eugene W.
    Lowe, Ross H.
    Darwin, W. David
    Herning, Ronald I.
    Cadet, Jean Lud
    Huestis, Marilyn A.
    [J]. JOURNAL OF ANALYTICAL TOXICOLOGY, 2009, 33 (08) : 469 - 477
  • [28] Addictions Neuroclinical Assessment: A Neuroscience-Based Framework for Addictive Disorders
    Kwako, Laura E.
    Momenan, Reza
    Litten, Raye Z.
    Koob, George F.
    Goldman, David
    [J]. BIOLOGICAL PSYCHIATRY, 2016, 80 (03) : 179 - 189
  • [29] The human brain revisited: Opportunities and challenges in postmortem studies of psychiatric disorders
    Lewis, DA
    [J]. NEUROPSYCHOPHARMACOLOGY, 2002, 26 (02) : 143 - 154
  • [30] Opioid use affects antioxidant activity and purine metabolism: preliminary results
    Mannelli, Paolo
    Patkar, Ashwin
    Rozen, Steve
    Matson, Wayne
    Krishnan, Ranga
    Kaddurah-Daouk, Rima
    [J]. HUMAN PSYCHOPHARMACOLOGY-CLINICAL AND EXPERIMENTAL, 2009, 24 (08) : 666 - 675